Market Overview

Regeneron Pharmaceuticals: Q3 Earnings Insights



Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 0.5% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 25.34% year over year to $8.36, which beat the estimate of $7.09.

Revenue of $2,294,000,000 rose by 12.01% from the same period last year, which beat the estimate of $2,090,000,000.


Regeneron Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 05, 2020

Time: 08:30 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $664.64

Company's 52-week low was at $310.74

Price action over last quarter: down 5.02%

Company Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.


Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: Earnings News